All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Polatuzumab vedotin in combination with R-CHP granted FDA approval for patients with untreated DLBCL

Apr 20, 2023

On April 19, 2023, it was announced that the U.S. Food and Drug Administration (FDA) had granted approval to polatuzumab vedotin, an antibody-drug conjugate, in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisolone) for the treatment of patients with previously untreated diffuse large B-cell lymphoma (DLBCL)-not otherwise specified or high-grade B-cell lymphoma who have an International Prognostic Index score of ≥2.1

Polatuzumab vedotin in combination with bendamustine and rituximab was previously granted accelerated approval by the U.S. FDA for the treatment of relapsed/refractory (R/R) DLBCL after at least two prior lines of therapy. Following the FDA Oncologic Drugs advisory committee (ODAC) vote (recently discussed by Grzegorz Nowakowski on the Lymphoma Hub) and results from the phase III POLARIX study (NCT03274492), the FDA has granted approval to polatuzumab vedotin plus R-CHP as a first-line treatment for DLBCL.1 In the POLARIX study, improvements in progression-free survival were seen with polatuzumab vedotin in combination with R-CHP compared with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone), with the R-CHP combination showing a 27% reduced risk of disease progression, relapse, or death.1 The adverse event profiles were comparable (Table 1). The most common AEs were peripheral neuropathy, nausea, fatigue, diarrhea, constipation, alopecia, and mucositis; the most common Grade 3–4 AEs were lymphopenia and neutropenia.1

Table 1. Safety profile of polatuzumab vedotin combined with R-CHP vs R-CHOP*


Polatuzumab vedotin + R-CHP


Grade 3–4 AEs



Serious AEs



Grade 5 AEs



AEs leading to dose reduction



AE, adverse event; R-CHP, rituximab, cyclophosphamide, doxorubicin, and prednisolone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.
*Data from Bussinesswire.1

  1.  FDA approves Genetech’s polivy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma. Published April 19, 2023. Accessed April 20, 2023.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox